The efficacy of single-dose therapy with 3 g of cephalexin was evaluated in 129 women with symptoms of acute uncomplicated lower urinary tract infections. Of 91 patients with significant bacteriuria, 61 Urinary tract infections (UTI) affect at least 10% of the female population and are among the most common infections seen in general medical practice during a lifetime. In general, they are easy to diagnose and can be effectively treated with many different antimicrobial agents; however, the dosage and length of treatment are still controversial.
Urinary tract infections (UTI) affect at least 10% of the female population and are among the most common infections seen in general medical practice during a lifetime. In general, they are easy to diagnose and can be effectively treated with many different antimicrobial agents; however, the dosage and length of treatment are still controversial.
Recently, several studies showed that a single-dose regimen is effective in treating acute uncomplicated UTI in a selected population of women (12, 13) . However, when unselected populations were studied, the single-dose regimen was less effective (6-8, 10, 11, 16) .
Henry Ford Hospital is a 950-bed, outpatient, general medical facility in the inner-city area of Detroit with several satellite clinics in the suburbs. Observations of the patients in this institution gave us the opportunity to study different population groups living within the same large metropolitan area. We chose to investigate the efficacy of a single oral dose of cephalexin in treating -acute uncomplicated UTI in women.
MATERIALS AND METHODS
Female patients who had symptoms suggestive of acute UTI (dysuria, frequency, hematuria) and had abnormal urinalysis results were entered in the study after informed consent was obtained. We excluded patients who were over 70 years ofage, were pregnant, or showed evidence of hepatic or renal impairment or other concomitant infection. We also excluded patients who had signs of acute pyelonephritis, had recently used antibiotics, or had a history of cephalosporin hypersensitivity or complicated UTI (e. g., nephrolithiasis, indwelling catheter, etc.). Initially, 129 patients were entered * Corresponding author.
in the study, but 4 were excluded from the final count because they were lost to follow-up. The remaining 125 patients were divided into three groups. Group 1 consisted of 91 patients whose pretreatment urine cultures yielded significant bacteriuria (.50,000 CFU/ml); they were classified as having an acute uncomplicated UTI. Group 2 consisted of28 patients whose pretreatment urine cultures contained .5,000 but <50,000 CFU of common uropathogens per ml; they were classified as having acute urethral syndrome due to bladder bacteriuria (14) . Group 3 included six patients whose voided-urine cultures were sterile; they were classified as having nonbacterial acute urethral syndrome.
Patients received cephalexin in a single 3-g dose given as 3 1-g tablets in the presence of one of the investigators. Clean voided-urine specimens were obtained immediately before, 48 to 72 h after, and 7 to 14 days after treatment for urinalysis and culturing. Side effects were recorded at each clinic visit.
The antibody-coated bacteria (ACB) test was performed on the original urine specimens by the technique described by Thomas et al. (15) . For the purpose of the present study, we required a positive test to show 4+ fluorescence with 100% of bacteria coated (J. Cardenas, D. Pohlod, and E. L. Quinn, Abstr. Annu. Meet. Am. Soc. Microbiol. 1983, A43, p. 8).
Outcome was considered satisfactory when symptoms and bacteriuria were resolved. Recurrence was defined as a reappearance of symptoms or a positive culture after a previously negative test. Recurrence with the same species was considered a relapse; recurrence was considered a reinfection if a new species of organism was cultured. Failure was defined as the persistence of symptoms or bacteriuria. Of patients with a positive ACB test, 17% were cured.
RESULTS
The pathogen most commonly found was Escherichia coli (81%). Of the E. coli strains, 6% were resistant to cephalexin. Other isolates included Proteus mirabilis (7%), Staphylococcus saprophyticus (4%), Klebsiella pneumoniae, (4%), and 1% each of Streptococcus group B, nonhemolytic streptococci, and Streptococcus group D. Of the patients, 2% had mixed infections.
Among the 91 patients with acute bacterial UTI (group 1), 87% (21 of 24) who were less than 25 years of age were cured (Table 1 ). In contrast, only 46% (11 of 24) of patients who were over 39 years of age (range, 40 to 75 years) were cured (P < 0.001). This difference was independent of a patient history of UTI (45 versus 33%, respectively). UTI in younger patients who were classified as a treatment failure or a recurrence were not due to cephalexin-resistant or antibody-coated bacteria. Only 1 of the 11 older patients had a UTI whose treatment was considered a failure; it was caused by a cephalexin-resistant strain. Three UTI in older patients were caused by antibody-coated bacteria. Treatment failure was thus related most closely to the age of the patient. In an analysis of age-related cure rates, Pauf et al. The efficacy of single-dose therapy in the 91 patients of all ages in group 1 was 67%. Other investigators reported cure rates of 54 to 79% with single-dose therapy of acute uncomplicated UTI in an unselected population of women (6-8, 10, 11, 16) . In these studies, cure rates for specific age groups were not reported, and variables such as the date of follow-up cultures were not uniform. Thus, a comparison of various studies was difficult. In all but one of the group 1 patients with positive cultures at 7 to 14 days UTI were caused by the same species of organism.
Only six of our patients had UTI caused by a cephalexinresistant strain, and six had UTI associated with a positive ACB test ( Finally, of the six patients with initially sterile urine samples (group 3), one failed to achieve symptomatic relief from the single dose of cephalexin.
A total of 125 patients who received a 3-g dose of cephalexin were observed for drug-related side effects. Nine patients (6.4%) complained of gastrointestinal side effects consisting primarily of epigastric discomfort and nausea that lasted for less than 4 h. One patient had loose stools for 4 days, but the relation with the medication was not clear. An additional four patients (2.8%) developed vaginal moniliasis.
DISCUSSION
The clinical efficacy of cephalexin in treating UTI has been documented in numerous reports (3, 17) . The lack of ACB test standarization makes a comparison between studies difficult. We used very strict criteria to define a positive test (4+ flourescence with 100% of bacteria coated) because we previously found that these criteria correlate best with the outcome of single-dose treatment (Cardenas et al., Abstr. Annu. Meet. Am. Soc. Microbiol. 1983). If we used parameters similar to those in other published reports (2+ fluorescence with -10% of bacteria coated), our overall results would not change significantly, but our success rate in treating ACB-positive patients would be 43% (6 of 14 cured) versus 17% (1 of 6 cured).
In our study, 28 patients had acute urethral syndrome due to bladder bacteriuria (14) . Twenty-seven patients (96%) responded satisfactorily to the single cephalexin dose. These results, although not placebo controlled, suggest that most of the cases of acute urethral syndrome in the population were due to infections manifested by low bacterial colony counts with common uropathogens.
Of further interest with regard to our patients was the close follow-up we were able to achieve for most patients because they belonged to a health maintenance organization and because their medical care was provided within our health care organization. No symptomatic recurrences were seen in these successfully treated study patients during at least 1 year of follow-up.
